TABLE 8.

Summary of the different in vivo experimental groups with their treatment regimens^a

Group	Formulation	Active compound	Vehicle	Administration route	Treatment regimen
1	Untreated control	None	None	None	None
2	AmBisome	Amphotericin B	Dextrose (5%)	Intravenous	25 mg/kg of body wt b.i.d., 5 doses
3	Leshcutan	Paromomycin sulfate (15%)	Methylbenzethonium chloride (12%) in petrolatum	Topical	0.1 ml 2 times/day for 10 days
4	Vehicle control	NA	E-PG (1:1)	Topical	50 μl 2 times/day for 10 days
5	Topical formulation 1	LSH001	Saturated drug solution in E-PG (1:1)	Topical	50 μl 2 times/day for 10 days
6	Topical formulation 2	LSH002	Saturated drug solution in E-PG (1:1)	Topical	50 μl 2 times/day for 10 days
7	Topical formulation 3	LSH003	Saturated drug solution in E-PG (1:1)	Topical	50 μl 2 times/day for 10 days
8	Oral formulation 1	LSH001	Standard suspended vehicle	Oral	25 mg/kg 2 times/day for 10 days
9	Oral formulation 2	LSH002	Standard suspended vehicle	Oral	25 mg/kg 2 times/day for 10 days
10	Oral formulation 3	LSH003	Standard suspended vehicle	Oral	25 mg/kg 2 times/day for 10 days

^ab.i.d., twice a day; NA, not applicable.